|12.81|| 0.00 / 0.00%|
TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. The TG-1101 is a third generation, type I chimeric IgG1 monoclonal antibody with a glycoengineered Fc region designed specifically to induce higher ADCC activity in comparison to rituximab, which has been demonstrated in pre-clinical models. The TGR-1202, is an orally available PI3K delta inhibitor. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.
|Michael S. Weiss||Executive Chairman, President & CEO|
|Sean A. Power||CFO, Secretary, Treasurer & CAO|
|Robert Niecestro||Executive Vice President-Clinical & Regulatory|
|Hari Miskin||Head-Business Development|
|Jenna A. Bosco||Director-Investor Relations|